Indication: cSSTI

cSSTI: complicated skin and soft tissue infections; CAP: community acquired pneumonia

References:
1. ZINFORO® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021;
2. Rosanova MT, et al. Ther Adv Infect Dis. 2019;6:2049936118808655;
3. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther 2012; 10:1087–103;
4. Laudano JB. J Antimicrob Chemother 2011; 66(Suppl. 3):iii11–iii18;
5. Drusano GL. J Antimicrob Chemother 2011; 66(Suppl. 3):iii61–7;
6. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother 2014; 58:2541–6;
7. Ishikawa T, Matsunaga N, Tawada H, et al. Bioorg Med Chem 2003;11:2427–37;
8. Moisan H, Pruneau M, Malouin F. J Antimicrob Chemother 2010;65:713–16.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.